{"id":25221,"date":"2026-06-15T01:25:00","date_gmt":"2026-06-15T01:25:00","guid":{"rendered":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/"},"modified":"2026-06-15T01:25:00","modified_gmt":"2026-06-15T01:25:00","slug":"%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4","status":"publish","type":"post","link":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/","title":{"rendered":"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b"},"content":{"rendered":"<p><span class=\"legendSpanClass\">\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde<\/span><span class=\"legendSpanClass\">2026\u5e746\u670815\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u6838\u5fc3\u4ea7\u54c1\u768417\u9879\u4e34\u5e8a\u8fdb\u5c55\u5df2\u57282026\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9879\u58c1\u62a5\u5c55\u793a\u3002\u5c55\u793a\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e24\u5927\u91cd\u78c5\u4ea7\u54c1\u2014\u2014\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u548c\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73b0\u4e86\u516c\u53f8\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6df1\u539a\u5e03\u5c40\u548c\u5168\u7403\u521b\u65b0\u5b9e\u529b\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>\u5728\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u53cc\u6cbb\u7597\u9886\u57df\u540c\u6b65\u66f4\u65b0\u5173\u952e\u5faa\u8bc1\u6570\u636e\uff1a\u5728CML\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u9488\u5bf9\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u5448\u73b0\u5f3a\u52b2\u7684\u4e8c\u7ebf\u6cbb\u7597\u6f5c\u529b\uff1b\u9488\u5bf9\u81f3\u5c11\u63a5\u53d7\u8fc72\u79cdTKI\u6cbb\u7597\u4e14\u6cbb\u7597\u5931\u8d25\u7684CML-CP\u60a3\u8005\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u4e3a\u4e00\u79cd\u6807\u51c6\u6cbb\u7597\uff1b\u540c\u65f6\u8be5\u4ea7\u54c1\u9488\u5bf9\u591a\u7ebfTKI\u8010\u836f\u3001\u5408\u5e76\u9ad8\u5371\u57fa\u56e0\u7a81\u53d8\u7684CML\u60a3\u8005\u7684\u4e34\u5e8a\u6570\u636e\u79ef\u6781\u3002\u5728Ph+ ALL\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u6301\u7eed\u5c55\u73b0\u7a33\u5065\u7597\u6548\uff0c\u5176\u4e00\u7ebf\u5168\u7403\u6ce8\u518c\u2162\u671f\uff08POLARIS-1\uff09\u6570\u636e\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u4f18\u5f02\u7684\u6df1\u5ea6\u7f13\u89e3\u7387\u4e0e\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u513f\u7ae5\u590d\u53d1\/\u96be\u6cbb\u6027Ph+ ALL\u7b49\u7ec6\u5206\u4eba\u7fa4\u4e2d\uff0c\u4e0e\u5229\u6c99\u6258\u514b\u62c9\u7684\u65e0\u5316\u7597\u8054\u5408\u65b9\u6848\u6536\u83b7\u4eae\u773c\u4e34\u5e8a\u6570\u636e\u3002<\/p>\n<p>\u5229\u6c99\u6258\u514b\u62c9\u9488\u5bf9\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u6ce8\u518c\u2161\u671f\u6570\u636e\u66f4\u65b0\uff0c\u901a\u8fc7\u57fa\u7ebf\u7279\u5f81\u4e0e\u9884\u540e\u76f8\u5173\u6027\u5206\u5c42\u5206\u6790\uff0c\u4e3a\u540e\u7eed\u7ec6\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u836f\u7b56\u7565\u3001\u4f18\u5316\u4e2a\u4f53\u5316\u7ed9\u836f\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4e5f\u4e3a\u5176\u4e34\u5e8a\u4ef7\u503c\u63d0\u4f9b\u4e86\u5f3a\u6709\u529b\u7684\u4f50\u8bc1\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a&#8221;\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u5f97\u5c55\u793a\uff0c\u8fdb\u4e00\u6b65\u8bc1\u5b9e\u4e86\u8fd9\u4e24\u6b3e\u91cd\u78c5\u4ea7\u54c1\u5728\u5168\u7403\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6cbb\u7597\u4ef7\u503c\u3002\u5965\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7597\u8def\u5f84\uff0c\u4e5f\u4e3aPh+ ALL\u60a3\u8005\u6cbb\u7597\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u6ce8\u518cII\u671f\u7684\u6570\u636e\u66f4\u65b0\u4e3a\u4e0d\u540c\u4eba\u7fa4\u7684\u4e2a\u4f53\u5316\u7528\u836f\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\uff0c\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4f7f\u6211\u4eec\u5bf9\u5176\u5728\u8fd9\u7c7b\u60a3\u8005\u7684\u5e94\u7528\u5145\u6ee1\u4fe1\u5fc3\u3002\u7279\u522b\u662f\u4e24\u4e2a\u4ea7\u54c1\u7684\u8054\u7528\u6570\u636e\u5448\u73b0\u7684\u5f3a\u52b2\u6f5c\u529b\u8ba9\u6211\u4eec\u500d\u611f\u5174\u594b\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u52a0\u901f\u63a8\u8fdb\u4e24\u4e2a\u91cd\u78c5\u4ea7\u54c1\u7684\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u540c\u65f6\u79ef\u6781\u63a2\u7d22\u66f4\u591a\u521b\u65b0\u8054\u5408\u6cbb\u7597\u65b9\u6848\uff0c\u4e3a\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u53d8\u9769\u610f\u4e49\u7684\u6cbb\u7597\u9009\u62e9\u3002&#8221;<\/p>\n<p>\u5728\u6b64\u6b21EHA\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u7cbe\u9009\u58c1\u62a5\u6838\u5fc3\u8981\u70b9\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u79cd\u76f8\u5173\u7814\u7a76\u6570\u636e\u8bf7\u67e5\u8be2EHA\u5b98\u7f51\uff09\uff1a<\/p>\n<p>UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)<\/p>\n<p>\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u4e3a\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7ebf\u6cbb\u7597\u7684\u6700\u65b0\u7597\u6548\u4e0e\u5b89\u5168\u6027<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEHA-3388 (PS1733)\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7eac\u660e\u6559\u6388\uff0c\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u534f\u548c\u533b\u9662\u8840\u6db2\u79d1\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u5355\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6807\u7b7e\u7684II\u671f\u7814\u7a76\uff0c\u8bc4\u4f30\u4e86\u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u65e0T315I\u7a81\u53d8\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08CCyR\uff09\u7387\u8fbe76.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\uff08MMR\uff09\u7387\u8fbe47.6%\uff0c\u4e14\u53cd\u5e94\u7387\u968f\u6cbb\u7597\u5468\u671f\u9012\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u65e0\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002\u8be5\u7814\u7a76\u8bc1\u660e\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u4e3a\u8fd9\u7c7b\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7ebf\u6cbb\u7597\u9009\u62e9\u3002<\/p>\n<p>EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS<\/p>\n<p>\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u65e2\u5f80\u5bf9\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u836f\u4e14\u643a\u5e26ASXL1\u57fa\u56e0\u7a81\u53d8\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7597\u6548<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEHA-3991 (PS1727)\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u56fd\u5fb7\u514b\u8428\u65af\u5927\u5b66MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879Ib\u671f\u7814\u7a76\uff0c\u5bf922\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u836f\u7684CP-CML\u60a3\u8005\u8fdb\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8bc4\u4f30\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u53d8\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\/22\uff09\u7684\u60a3\u8005\u643a\u5e26ASXL1\u7a81\u53d8\u3002\u7ecf\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u540e\uff0c44.4%\uff084\/9\uff09\u7684ASXL1\u7a81\u53d8\u60a3\u8005\u83b7\u5f97\u4e34\u5e8a\u53cd\u5e94\uff0c\u5176\u4e2d22.2%\uff082\/9\uff09\u8fbe\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u8fbe\u5230MR4.5\uff09\u3002\u8be5\u7814\u7a76\u9996\u6b21\u8bc1\u660e\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5bf9\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u836f\u4e14\u643a\u5e26ASXL1\u7a81\u53d8\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u4e3a\u591a\u91cdTKI\u8010\u836f\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u3002<\/p>\n<p>THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL<\/p>\n<p>\u7ecf\u81f3\u5c11\u4e24\u79cd\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u6cbb\u7597\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f6c\u6362\u7528\u5965\u96f7\u5df4\u66ff\u5c3c\u6216\u7ee7\u7eed\u539fTKI\u6cbb\u7597\u7684\u7597\u6548\u4e0e\u5b89\u5168\u6027\uff1a\u4e00\u9879\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5bf9\u7167\u7814\u7a76<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEHA-4595 (PS1728)\u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u533b\u9662\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5bf9\u7167\u8bd5\u9a8c\uff0c\u7eb3\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u79cdTKI\u6cbb\u7597\u226518\u4e2a\u6708\u4f46\u672a\u8fbeMMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5965\u96f7\u5df4\u66ff\u5c3c\u7ec4\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7ee7\u7eed\u539fTKI\u6cbb\u7597\u7ec4\u3002\u7ed3\u679c\u663e\u793a\uff0c6\u4e2a\u6708\u65f6\u5965\u96f7\u5df4\u66ff\u5c3c\u7ec4MMR\u7387\u663e\u8457\u9ad8\u4e8e\u5bf9\u7167\u7ec4\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u4e2a\u6708\u65f6\u7d2f\u79efMMR\u7387\u5206\u522b\u4e3a57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u89c13-4\u7ea7\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u4e3a\u8840\u5c0f\u677f\u51cf\u5c11\uff0842.86%\uff09\u548c\u8d2b\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b66\u4e8b\u4ef6\u7f55\u89c1\u300278.57%\u7684\u60a3\u8005\u5728\u6362\u7528\u5965\u96f7\u5df4\u66ff\u5c3c\u540e\uff0c\u65e2\u5f80TKI\u76f8\u5173AE\u5f97\u5230\u6539\u5584\u3002\u7ed3\u8bba\u652f\u6301\u5965\u96f7\u5df4\u66ff\u5c3c\u4f5c\u4e3a\u22652\u79cdTKI\u6cbb\u7597\u5931\u8d25CML-CP\u60a3\u8005\u7684\u6f5c\u5728\u6807\u51c6\u6cbb\u7597\u3002<\/p>\n<p>UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL<\/p>\n<p>POLARIS-1\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7ed3\u679c\uff1a\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u4f4e\u5f3a\u5ea6\u5316\u7597\u6cbb\u7597\u65b0\u8bca\u65ad\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7684\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEHA-3437 (PS1479)\u7b2c\u4e00\u4f5c\u8005\uff1a\u9648\u82cf\u5b81\u6559\u6388\uff0c\u82cf\u5dde\u5927\u5b66\u9644\u5c5e\u7b2c\u4e00\u533b\u9662\u8fd9\u662f\u4e00\u9879\u5168\u7403\u591a\u4e2d\u5fc3\u6ce8\u518c\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8bc4\u4f30\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u4f4e\u5f3a\u5ea6\u5316\u7597\u7528\u4e8e\u65b0\u8bca\u65adPh+ ALL\u7684\u7597\u6548\u4e0e\u5b89\u5168\u6027\u3002\u5171\u5165\u7ec455\u4f8b\u60a3\u8005\uff0c\u8bf1\u5bfc\u6cbb\u7597\u7ed3\u675f\u65f6CR\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b8b\u7559\u75c5\uff08MRD\uff09\u9634\u6027CR\u738763.0%\uff1b MRD\u9634\u6027\u7387\u968f\u6cbb\u7597\u5468\u671f\u63a8\u8fdb\u6301\u7eed\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7597\u5468\u671f\u672b\u8fbe93.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u4e0e40mg\u5242\u91cf\u7ec4\u7597\u6548\u4e0e\u5b89\u5168\u6027\u65e0\u663e\u8457\u5dee\u5f02\uff0c\u4e14\u5bf9IKZF1plus\u7b49\u4e0d\u826f\u9884\u540e\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6837\u9ad8\u6548\u3002\u8be5\u7814\u7a76\u8bc1\u660e\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u4f4e\u5f3a\u5ea6\u5316\u7597\u53ef\u4e3a\u65b0\u8bca\u65adPh+ ALL\u60a3\u8005\u5e26\u6765\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f6c\u9634\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u4e3aPh+ ALL\u4e00\u7ebf\u6cbb\u7597\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u636e\u3002<\/p>\n<p>SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\/REFRACTORY (R\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY<\/p>\n<p>\u4e00\u98791B\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff1a\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\uff08R\/R\uff09\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u513f\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u4e0e\u521d\u6b65\u7597\u6548<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEHA-4691 (PS1473)\u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u8840\u6db2\u75c5\u533b\u9662\uff08\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u8840\u6db2\u5b66\u7814\u7a76\u6240\uff09\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u5f00\u653e\u6807\u7b7e\u3001\u5242\u91cf\u9012\u589eIb\u671f\u7814\u7a76\u8bc4\u4f30\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7597\u65e2\u5f80\u22651\u79cdTKI\u8010\u836f\u6216\u4e0d\u8010\u53d7\u7684\u513f\u7ae5R\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7ec417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f8413\u5c81\uff0c40%\u643a\u5e26ABL1\u7a81\u53d8\uff08\u542bT315I\uff09\u30029\u4f8b\u53ef\u8bc4\u4f30\u7597\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u8054\u5408\u6cbb\u7597\u540eORR\u9ad8\u8fbe88.9%\uff0cMRD\u9634\u6027\u7387\u8fbe66.7%\uff088\/12\uff0c\u7b2c2\u5468\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u513f\uff0814\/15\uff0c\u7b2c2\u5468\u671f\u7b2c28\u5929\uff09\u83b7\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7f13\u89e3\uff1b\u4e24\u836f\u5747\u53ef\u900f\u8fc7\u8840\u8111\u5c4f\u969c\uff0c\u5bf9ABL1\u7a81\u53d8\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u65e0\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002\u8be5\u7814\u7a76\u8bc1\u660e\uff0c\u8be5\u65e0\u5316\u7597\u53e3\u670d\u53cc\u9776\u5411\u65b9\u6848\u53ef\u5e26\u6765\u5feb\u901f\u3001\u6df1\u5ea6\u7f13\u89e3\uff0c\u4e3a\u513f\u7ae5R\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7597\u9009\u62e9\u3002<\/p>\n<p>REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY<\/p>\n<p>\u4e00\u9879\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u4e8e\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u7597\u6548\u4e0e\u5b89\u5168\u6027<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEHA-5454 (PF562)\u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u4e1c\u5927\u5b66\u9f50\u9c81\u533b\u9662\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u56fd\u5185\u591a\u4e2d\u5fc3\u771f\u5b9e\u4e16\u754c\u7814\u7a76\uff08\u56de\u987e\u6027\uff09\uff0c\u65e8\u5728\u8bc4\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u80bf\u7624\u4e2d\u7684\u7597\u6548\u4e0e\u5b89\u5168\u6027\u3002\u5171\u7eb3\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f84\u4e3a63\u5c81\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u5355\u6838\u7ec6\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\/CRi\u9ad8\u8fbe72%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7ec4\u7597\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u8fbe\u5230CR\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9634\u6027\u7387\u8fbe61%\u3002NPM1\u7a81\u53d8\u60a3\u8005CR\/CRi\u7387\u4e3a100%\uff0cIDH2 \u7a81\u53d8\u60a3\u8005\u4e3a83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u8fbe\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7ea7\u6cbb\u7597\u671f\u95f4\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u4e3a\u8840\u7ec6\u80de\u51cf\u5c11\uff08\u8840\u5c0f\u677f\u51cf\u5c1127%\uff0c\u8d2b\u884023%\uff0c\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c1120%\uff09\uff0c\u6574\u4f53\u53ef\u63a7\u3002\u8be5\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5b9e\u4e16\u754c\u4e2d\u6cbb\u7597\u9ad3\u7cfb\u80bf\u7624\uff08\u7279\u522b\u662fAML\uff09\u5177\u6709\u4f18\u5f02\u7684\u7597\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002<\/p>\n<p>CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY<\/p>\n<p>\u4e00\u9879\u5173\u952eII\u671f\u4e34\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7597\u7684\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u57fa\u7ebf\u7279\u5f81\u4e0e\u9884\u540e\u7684\u76f8\u5173\u6027<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aEHA-3984 (PS1713)\u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6811\u6559\u6388\uff0c\u6cb3\u5357\u7701\u80bf\u7624\u533b\u9662\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u57fa\u4e8e\u5173\u952eII\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u5173\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u65f6\u57fa\u7ebf\u7279\u5f81\u4e0e\u9884\u540e\u7684\u5173\u7cfb\u3002\u7814\u7a76\u7eb3\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7597\u5931\u8d25\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7597\u3002\u572872\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u4e3a23.9\u4e2a\u6708\uff0cIRC\u8bc4\u4f30ORR\u4e3a62.5%\u3002\u8fdb\u4e00\u6b65\u5206\u6790\u663e\u793a\uff0cTP53\u7a81\u53d8\/del(17p)\u3001\u590d\u6742\u6838\u578b\u3001\u57fa\u6570\u8f83\u5927\u7684\u80bf\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u53d8\u4e0e\u8f83\u5dee\u9884\u540e\u76f8\u5173\uff0c\u5176\u4e2d\u590d\u6742\u6838\u578b\u548c\u80bf\u7624\u5927\u5c0f\u662fPFS\u7f29\u77ed\u7684\u72ec\u7acb\u98ce\u9669\u56e0\u7d20\u3002\u8be5\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7597\u5931\u8d25\u540e\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u786e\u7597\u6548\uff0c\u5e76\u53ef\u901a\u8fc7\u57fa\u7ebf\u98ce\u9669\u7279\u5f81\u8fdb\u4e00\u6b65\u8bc6\u522b\u9884\u540e\u8f83\u5dee\u4eba\u7fa4\uff0c\u4e3a\u540e\u7eed\u98ce\u9669\u5206\u5c42\u548c\u8054\u5408\u6cbb\u7597\u7b56\u7565\u63d0\u4f9b\u4f9d\u636e\u3002<\/p>\n<p>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/p>\n<p>\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u662f\u4e00\u5bb6\u7efc\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u7814\u53d1\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316\u521b\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u80bf\u7624\u9886\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e30\u5bcc\u7684\u521b\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\u3001\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5242\u3002<\/p>\n<p>\u516c\u53f8\u6838\u5fc3\u54c1\u79cd\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u5df2\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u4f34\u6709T315I\u7a81\u53d8\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5bf9\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8be5\u836f\u7269\u6240\u6709\u83b7\u6279\u9002\u5e94\u75c7\u5747\u5df2\u88ab\u7eb3\u5165\u4e2d\u56fd\u56fd\u5bb6\u533b\u4fdd\u836f\u54c1\u76ee\u5f55\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u6b63\u5728\u5f00\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9879\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u5206\u522b\u4e3a\uff1a\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u8bb8\u53ef\u7684\u8bc4\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7597\u65b0\u8bca\u65ad\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u8bb8\u53ef\u7684\u8bc4\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7597\u7ecf\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8bc4\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7597SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002<\/p>\n<p>\u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u79cd\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u4e8e\u6cbb\u7597\u591a\u79cd\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5242\u3002\u5229\u751f\u59a5\u00ae\u5df2\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u79cd\u5305\u62ec\u5e03\u9c81\u987f\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5242\u5728\u5185\u7684\u7cfb\u7edf\u6cbb\u7597\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u6b63\u5728\u5f00\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9879\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u5206\u522b\u4e3a\uff1a\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u8bb8\u53ef\u7684\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u8054\u5408BTK\u6291\u5236\u5242\u6cbb\u7597\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5242\u6cbb\u7597\u8d85\u8fc712\u4e2a\u6708\u4e14\u5e94\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7ebf\u6cbb\u7597\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u8bb8\u53ef\u7684\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002<\/p>\n<p>\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0e\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u4e1c\u3001\u8f89\u745e\u3001\u4fe1\u8fbe\u7b49\u4f17\u591a\u9886\u5148\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u8fbe\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u65f6\u4e0e\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u3001\u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b66\u7b49\u5b66\u672f\u673a\u6784\u5efa\u7acb\u7814\u53d1\u5408\u4f5c\u5173\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee\u00a0<a href=\"https:\/\/ascentage.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/ascentage.com\/<\/a><\/p>\n<p>\u524d\u77bb\u6027\u58f0\u660e<\/p>\n<p>\u672c\u65b0\u95fb\u7a3f\u5305\u542b\u6839\u636e\u7f8e\u56fd\u300a1995\u5e74\u79c1\u4eba\u8bc1\u5238\u8bc9\u8bbc\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7ecf\u4fee\u8ba2\u7684\u300a1933\u5e74\u8bc1\u5238\u6cd5\u300b\u7b2c27A\u6761\u548c\u300a1934\u5e74\u8bc1\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u6761\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9648\u8ff0\u3002\u9664\u5386\u53f2\u4e8b\u5b9e\u9648\u8ff0\u5916\uff0c\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u6240\u6709\u5185\u5bb9\u5747\u53ef\u80fd\u6784\u6210\u524d\u77bb\u6027\u9648\u8ff0\uff0c\u5305\u62ec\u4e9a\u76db\u533b\u836f\u5bf9\u672a\u6765\u4e8b\u4ef6\u3001\u7ecf\u8425\u6210\u679c\u6216\u8d22\u52a1\u72b6\u51b5\u6240\u53d1\u8868\u7684\u610f\u89c1\u3001\u9884\u671f\u3001\u4fe1\u5ff5\u3001\u8ba1\u5212\u3001\u76ee\u6807\u3001\u5047\u8bbe\u6216\u9884\u6d4b\u3002<\/p>\n<p>\u8fd9\u4e9b\u524d\u77bb\u6027\u9648\u8ff0\u53d7\u5230\u8bf8\u591a\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u7684\u5f71\u54cd\uff0c\u5177\u4f53\u5185\u5bb9\u5df2\u5728\u4e9a\u76db\u533b\u836f\u5411\u7f8e\u56fd\u8bc1\u5238\u4ea4\u6613\u59d4\u5458\u4f1a\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8be6\u7ec6\u8bf4\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u62a5\u544a\u4e2d\u7684&#8221;\u98ce\u9669\u56e0\u7d20&#8221;\u548c&#8221;\u5173\u4e8e\u524d\u77bb\u6027\u58f0\u660e\u7684\u8b66\u793a\u58f0\u660e&#8221;\u7ae0\u8282\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u53d1\u884c\u4e0a\u5e02\u62db\u80a1\u4e66\u4e2d\u7684&#8221;\u524d\u77bb\u6027\u58f0\u660e&#8221;\u3001&#8221;\u98ce\u9669\u56e0\u7d20&#8221;\u7ae0\u8282\uff0c\u4ee5\u53ca\u6211\u4eec\u4e0d\u65f6\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u8fd9\u4e9b\u56e0\u7d20\u53ef\u80fd\u5bfc\u81f4\u5b9e\u9645\u4e1a\u7ee9\u3001\u8fd0\u8425\u6c34\u5e73\u3001\u7ecf\u8425\u6210\u679c\u6216\u6210\u5c31\u4e0e\u524d\u77bb\u6027\u9648\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u5f02\u3002\u672c\u524d\u77bb\u6027\u58f0\u660e\u4e2d\u7684\u9648\u8ff0\u4e0d\u6784\u6210\u516c\u53f8\u7ba1\u7406\u5c42\u7684\u5229\u6da6\u9884\u6d4b\u3002<\/p>\n<p>\u56e0\u6b64\uff0c\u8be5\u7b49\u524d\u77bb\u6027\u9648\u8ff0\u4e0d\u5e94\u88ab\u89c6\u4e3a\u5bf9\u672a\u6765\u4e8b\u4ef6\u7684\u9884\u6d4b\u3002\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u57fa\u4e8e\u4e9a\u76db\u533b\u836f\u5f53\u524d\u5bf9\u672a\u6765\u53d1\u5c55\u53ca\u5176\u6f5c\u5728\u5f71\u54cd\u7684\u9884\u671f\u548c\u5224\u65ad\uff0c\u4e14\u4ec5\u4ee3\u8868\u622a\u81f3\u9648\u8ff0\u53d1\u8868\u4e4b\u65e5\u7684\u89c2\u70b9\u3002\u65e0\u8bba\u51fa\u73b0\u65b0\u4fe1\u606f\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u4e9a\u76db\u533b\u836f\u5747\u65e0\u4e49\u52a1\u66f4\u65b0\u6216\u4fee\u8ba2\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u3002<\/p>\n<p>SOURCE \u4e9a\u76db\u533b\u836f<\/p>","protected":false},"excerpt":{"rendered":"<p>\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u6838\u5fc3\u4ea7\u54c1\u768417\u9879\u4e34\u5e8a\u8fdb\u5c55\u5df2\u57282026\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9879\u58c1\u62a5\u5c55\u793a\u3002\u5c55\u793a\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e24\u5927\u91cd\u78c5\u4ea7\u54c1\u2014\u2014\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u548c\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73b0\u4e86\u516c\u53f8\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6df1\u539a\u5e03\u5c40\u548c\u5168\u7403\u521b\u65b0\u5b9e\u529b\u3002 \u5728\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u53cc\u6cbb\u7597\u9886\u57df\u540c\u6b65\u66f4\u65b0\u5173\u952e\u5faa\u8bc1\u6570\u636e\uff1a\u5728CML\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u9488\u5bf9\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u5448\u73b0\u5f3a\u52b2\u7684\u4e8c\u7ebf\u6cbb\u7597\u6f5c\u529b\uff1b\u9488\u5bf9\u81f3\u5c11\u63a5\u53d7\u8fc72\u79cdTKI\u6cbb\u7597\u4e14\u6cbb\u7597\u5931\u8d25\u7684CML-CP\u60a3\u8005\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u4e3a\u4e00\u79cd\u6807\u51c6\u6cbb\u7597\uff1b\u540c\u65f6\u8be5\u4ea7\u54c1\u9488\u5bf9\u591a\u7ebfTKI\u8010\u836f\u3001\u5408\u5e76\u9ad8\u5371\u57fa\u56e0\u7a81\u53d8\u7684CML\u60a3\u8005\u7684\u4e34\u5e8a\u6570\u636e\u79ef\u6781\u3002\u5728Ph+ ALL\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u6301\u7eed\u5c55\u73b0\u7a33\u5065\u7597\u6548\uff0c\u5176\u4e00\u7ebf\u5168\u7403\u6ce8\u518c\u2162\u671f\uff08POLARIS-1\uff09\u6570\u636e\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u4f18\u5f02\u7684\u6df1\u5ea6\u7f13\u89e3\u7387\u4e0e\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u513f\u7ae5\u590d\u53d1\/\u96be\u6cbb\u6027Ph+ ALL\u7b49\u7ec6\u5206\u4eba\u7fa4\u4e2d\uff0c\u4e0e\u5229\u6c99\u6258\u514b\u62c9\u7684\u65e0\u5316\u7597\u8054\u5408\u65b9\u6848\u6536\u83b7\u4eae\u773c\u4e34\u5e8a\u6570\u636e\u3002 \u5229\u6c99\u6258\u514b\u62c9\u9488\u5bf9\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u6ce8\u518c\u2161\u671f\u6570\u636e\u66f4\u65b0\uff0c\u901a\u8fc7\u57fa\u7ebf\u7279\u5f81\u4e0e\u9884\u540e\u76f8\u5173\u6027\u5206\u5c42\u5206\u6790\uff0c\u4e3a\u540e\u7eed\u7ec6\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u836f\u7b56\u7565\u3001\u4f18\u5316\u4e2a\u4f53\u5316\u7ed9\u836f\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4e5f\u4e3a\u5176\u4e34\u5e8a\u4ef7\u503c\u63d0\u4f9b\u4e86\u5f3a\u6709\u529b\u7684\u4f50\u8bc1\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a&#8221;\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u5f97\u5c55\u793a\uff0c\u8fdb\u4e00\u6b65\u8bc1\u5b9e\u4e86\u8fd9\u4e24\u6b3e\u91cd\u78c5\u4ea7\u54c1\u5728\u5168\u7403\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6cbb\u7597\u4ef7\u503c\u3002\u5965\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7597\u8def\u5f84\uff0c\u4e5f\u4e3aPh+ ALL\u60a3\u8005\u6cbb\u7597\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u6ce8\u518cII\u671f\u7684\u6570\u636e\u66f4\u65b0\u4e3a\u4e0d\u540c\u4eba\u7fa4\u7684\u4e2a\u4f53\u5316\u7528\u836f\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\uff0c\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4f7f\u6211\u4eec\u5bf9\u5176\u5728\u8fd9\u7c7b\u60a3\u8005\u7684\u5e94\u7528\u5145\u6ee1\u4fe1\u5fc3\u3002\u7279\u522b\u662f\u4e24\u4e2a\u4ea7\u54c1\u7684\u8054\u7528\u6570\u636e\u5448\u73b0\u7684\u5f3a\u52b2\u6f5c\u529b\u8ba9\u6211\u4eec\u500d\u611f\u5174\u594b\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u52a0\u901f\u63a8\u8fdb\u4e24\u4e2a\u91cd\u78c5\u4ea7\u54c1\u7684\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u540c\u65f6\u79ef\u6781\u63a2\u7d22\u66f4\u591a\u521b\u65b0\u8054\u5408\u6cbb\u7597\u65b9\u6848\uff0c\u4e3a\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u53d8\u9769\u610f\u4e49\u7684\u6cbb\u7597\u9009\u62e9\u3002&#8221; \u5728\u6b64\u6b21EHA\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u7cbe\u9009\u58c1\u62a5\u6838\u5fc3\u8981\u70b9\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u79cd\u76f8\u5173\u7814\u7a76\u6570\u636e\u8bf7\u67e5\u8be2EHA\u5b98\u7f51\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u4e3a\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7ebf\u6cbb\u7597\u7684\u6700\u65b0\u7597\u6548\u4e0e\u5b89\u5168\u6027 \u6458\u8981\u7f16\u53f7\uff1aEHA-3388 (PS1733)\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7eac\u660e\u6559\u6388\uff0c\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u534f\u548c\u533b\u9662\u8840\u6db2\u79d1\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u5355\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6807\u7b7e\u7684II\u671f\u7814\u7a76\uff0c\u8bc4\u4f30\u4e86\u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u65e0T315I\u7a81\u53d8\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08CCyR\uff09\u7387\u8fbe76.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\uff08MMR\uff09\u7387\u8fbe47.6%\uff0c\u4e14\u53cd\u5e94\u7387\u968f\u6cbb\u7597\u5468\u671f\u9012\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u65e0\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002\u8be5\u7814\u7a76\u8bc1\u660e\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u4e3a\u8fd9\u7c7b\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7ebf\u6cbb\u7597\u9009\u62e9\u3002 EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u65e2\u5f80\u5bf9\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u836f\u4e14\u643a\u5e26ASXL1\u57fa\u56e0\u7a81\u53d8\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7597\u6548 [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":25222,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-25221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b - Money Compass CN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/moneycompass.com.my\/cn\/\u3010eha2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b - Money Compass CN\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u6838\u5fc3\u4ea7\u54c1\u768417\u9879\u4e34\u5e8a\u8fdb\u5c55\u5df2\u57282026\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9879\u58c1\u62a5\u5c55\u793a\u3002\u5c55\u793a\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e24\u5927\u91cd\u78c5\u4ea7\u54c1\u2014\u2014\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u548c\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73b0\u4e86\u516c\u53f8\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6df1\u539a\u5e03\u5c40\u548c\u5168\u7403\u521b\u65b0\u5b9e\u529b\u3002 \u5728\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u53cc\u6cbb\u7597\u9886\u57df\u540c\u6b65\u66f4\u65b0\u5173\u952e\u5faa\u8bc1\u6570\u636e\uff1a\u5728CML\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u9488\u5bf9\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u5448\u73b0\u5f3a\u52b2\u7684\u4e8c\u7ebf\u6cbb\u7597\u6f5c\u529b\uff1b\u9488\u5bf9\u81f3\u5c11\u63a5\u53d7\u8fc72\u79cdTKI\u6cbb\u7597\u4e14\u6cbb\u7597\u5931\u8d25\u7684CML-CP\u60a3\u8005\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u4e3a\u4e00\u79cd\u6807\u51c6\u6cbb\u7597\uff1b\u540c\u65f6\u8be5\u4ea7\u54c1\u9488\u5bf9\u591a\u7ebfTKI\u8010\u836f\u3001\u5408\u5e76\u9ad8\u5371\u57fa\u56e0\u7a81\u53d8\u7684CML\u60a3\u8005\u7684\u4e34\u5e8a\u6570\u636e\u79ef\u6781\u3002\u5728Ph+ ALL\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u6301\u7eed\u5c55\u73b0\u7a33\u5065\u7597\u6548\uff0c\u5176\u4e00\u7ebf\u5168\u7403\u6ce8\u518c\u2162\u671f\uff08POLARIS-1\uff09\u6570\u636e\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u4f18\u5f02\u7684\u6df1\u5ea6\u7f13\u89e3\u7387\u4e0e\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u513f\u7ae5\u590d\u53d1\/\u96be\u6cbb\u6027Ph+ ALL\u7b49\u7ec6\u5206\u4eba\u7fa4\u4e2d\uff0c\u4e0e\u5229\u6c99\u6258\u514b\u62c9\u7684\u65e0\u5316\u7597\u8054\u5408\u65b9\u6848\u6536\u83b7\u4eae\u773c\u4e34\u5e8a\u6570\u636e\u3002 \u5229\u6c99\u6258\u514b\u62c9\u9488\u5bf9\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u6ce8\u518c\u2161\u671f\u6570\u636e\u66f4\u65b0\uff0c\u901a\u8fc7\u57fa\u7ebf\u7279\u5f81\u4e0e\u9884\u540e\u76f8\u5173\u6027\u5206\u5c42\u5206\u6790\uff0c\u4e3a\u540e\u7eed\u7ec6\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u836f\u7b56\u7565\u3001\u4f18\u5316\u4e2a\u4f53\u5316\u7ed9\u836f\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4e5f\u4e3a\u5176\u4e34\u5e8a\u4ef7\u503c\u63d0\u4f9b\u4e86\u5f3a\u6709\u529b\u7684\u4f50\u8bc1\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a&#8221;\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u5f97\u5c55\u793a\uff0c\u8fdb\u4e00\u6b65\u8bc1\u5b9e\u4e86\u8fd9\u4e24\u6b3e\u91cd\u78c5\u4ea7\u54c1\u5728\u5168\u7403\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6cbb\u7597\u4ef7\u503c\u3002\u5965\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7597\u8def\u5f84\uff0c\u4e5f\u4e3aPh+ ALL\u60a3\u8005\u6cbb\u7597\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u6ce8\u518cII\u671f\u7684\u6570\u636e\u66f4\u65b0\u4e3a\u4e0d\u540c\u4eba\u7fa4\u7684\u4e2a\u4f53\u5316\u7528\u836f\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\uff0c\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4f7f\u6211\u4eec\u5bf9\u5176\u5728\u8fd9\u7c7b\u60a3\u8005\u7684\u5e94\u7528\u5145\u6ee1\u4fe1\u5fc3\u3002\u7279\u522b\u662f\u4e24\u4e2a\u4ea7\u54c1\u7684\u8054\u7528\u6570\u636e\u5448\u73b0\u7684\u5f3a\u52b2\u6f5c\u529b\u8ba9\u6211\u4eec\u500d\u611f\u5174\u594b\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u52a0\u901f\u63a8\u8fdb\u4e24\u4e2a\u91cd\u78c5\u4ea7\u54c1\u7684\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u540c\u65f6\u79ef\u6781\u63a2\u7d22\u66f4\u591a\u521b\u65b0\u8054\u5408\u6cbb\u7597\u65b9\u6848\uff0c\u4e3a\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u53d8\u9769\u610f\u4e49\u7684\u6cbb\u7597\u9009\u62e9\u3002&#8221; \u5728\u6b64\u6b21EHA\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u7cbe\u9009\u58c1\u62a5\u6838\u5fc3\u8981\u70b9\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u79cd\u76f8\u5173\u7814\u7a76\u6570\u636e\u8bf7\u67e5\u8be2EHA\u5b98\u7f51\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u4e3a\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7ebf\u6cbb\u7597\u7684\u6700\u65b0\u7597\u6548\u4e0e\u5b89\u5168\u6027 \u6458\u8981\u7f16\u53f7\uff1aEHA-3388 (PS1733)\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7eac\u660e\u6559\u6388\uff0c\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u534f\u548c\u533b\u9662\u8840\u6db2\u79d1\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u5355\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6807\u7b7e\u7684II\u671f\u7814\u7a76\uff0c\u8bc4\u4f30\u4e86\u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u65e0T315I\u7a81\u53d8\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08CCyR\uff09\u7387\u8fbe76.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\uff08MMR\uff09\u7387\u8fbe47.6%\uff0c\u4e14\u53cd\u5e94\u7387\u968f\u6cbb\u7597\u5468\u671f\u9012\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u65e0\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002\u8be5\u7814\u7a76\u8bc1\u660e\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u4e3a\u8fd9\u7c7b\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7ebf\u6cbb\u7597\u9009\u62e9\u3002 EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u65e2\u5f80\u5bf9\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u836f\u4e14\u643a\u5e26ASXL1\u57fa\u56e0\u7a81\u53d8\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7597\u6548 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/moneycompass.com.my\/cn\/\u3010eha2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\/\" \/>\n<meta property=\"og:site_name\" content=\"Money Compass CN\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T01:25:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/\",\"name\":\"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b - Money Compass CN\",\"isPartOf\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-wvESxR.jpeg\",\"datePublished\":\"2026-06-15T01:25:00+00:00\",\"dateModified\":\"2026-06-15T01:25:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#primaryimage\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-wvESxR.jpeg\",\"contentUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-wvESxR.jpeg\",\"width\":144,\"height\":54},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/moneycompass.com.my\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/\",\"name\":\"Money Compass CN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b - Money Compass CN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/moneycompass.com.my\/cn\/\u3010eha2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\/","og_locale":"en_US","og_type":"article","og_title":"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b - Money Compass CN","og_description":"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u6838\u5fc3\u4ea7\u54c1\u768417\u9879\u4e34\u5e8a\u8fdb\u5c55\u5df2\u57282026\u5e74\u6b27\u6d32\u8840\u6db2\u5b66\u534f\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9879\u58c1\u62a5\u5c55\u793a\u3002\u5c55\u793a\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e24\u5927\u91cd\u78c5\u4ea7\u54c1\u2014\u2014\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u548c\u4e2d\u56fd\u9996\u4e2a\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73b0\u4e86\u516c\u53f8\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6df1\u539a\u5e03\u5c40\u548c\u5168\u7403\u521b\u65b0\u5b9e\u529b\u3002 \u5728\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u53cc\u6cbb\u7597\u9886\u57df\u540c\u6b65\u66f4\u65b0\u5173\u952e\u5faa\u8bc1\u6570\u636e\uff1a\u5728CML\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u9488\u5bf9\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u5448\u73b0\u5f3a\u52b2\u7684\u4e8c\u7ebf\u6cbb\u7597\u6f5c\u529b\uff1b\u9488\u5bf9\u81f3\u5c11\u63a5\u53d7\u8fc72\u79cdTKI\u6cbb\u7597\u4e14\u6cbb\u7597\u5931\u8d25\u7684CML-CP\u60a3\u8005\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u4e3a\u4e00\u79cd\u6807\u51c6\u6cbb\u7597\uff1b\u540c\u65f6\u8be5\u4ea7\u54c1\u9488\u5bf9\u591a\u7ebfTKI\u8010\u836f\u3001\u5408\u5e76\u9ad8\u5371\u57fa\u56e0\u7a81\u53d8\u7684CML\u60a3\u8005\u7684\u4e34\u5e8a\u6570\u636e\u79ef\u6781\u3002\u5728Ph+ ALL\u9886\u57df\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u6301\u7eed\u5c55\u73b0\u7a33\u5065\u7597\u6548\uff0c\u5176\u4e00\u7ebf\u5168\u7403\u6ce8\u518c\u2162\u671f\uff08POLARIS-1\uff09\u6570\u636e\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u4f18\u5f02\u7684\u6df1\u5ea6\u7f13\u89e3\u7387\u4e0e\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u513f\u7ae5\u590d\u53d1\/\u96be\u6cbb\u6027Ph+ ALL\u7b49\u7ec6\u5206\u4eba\u7fa4\u4e2d\uff0c\u4e0e\u5229\u6c99\u6258\u514b\u62c9\u7684\u65e0\u5316\u7597\u8054\u5408\u65b9\u6848\u6536\u83b7\u4eae\u773c\u4e34\u5e8a\u6570\u636e\u3002 \u5229\u6c99\u6258\u514b\u62c9\u9488\u5bf9\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u6ce8\u518c\u2161\u671f\u6570\u636e\u66f4\u65b0\uff0c\u901a\u8fc7\u57fa\u7ebf\u7279\u5f81\u4e0e\u9884\u540e\u76f8\u5173\u6027\u5206\u5c42\u5206\u6790\uff0c\u4e3a\u540e\u7eed\u7ec6\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u836f\u7b56\u7565\u3001\u4f18\u5316\u4e2a\u4f53\u5316\u7ed9\u836f\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4e5f\u4e3a\u5176\u4e34\u5e8a\u4ef7\u503c\u63d0\u4f9b\u4e86\u5f3a\u6709\u529b\u7684\u4f50\u8bc1\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a&#8221;\u672c\u5c4aEHA\u5e74\u4f1a\u4e0a\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u5f97\u5c55\u793a\uff0c\u8fdb\u4e00\u6b65\u8bc1\u5b9e\u4e86\u8fd9\u4e24\u6b3e\u91cd\u78c5\u4ea7\u54c1\u5728\u5168\u7403\u8840\u6db2\u80bf\u7624\u9886\u57df\u7684\u6cbb\u7597\u4ef7\u503c\u3002\u5965\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7597\u8def\u5f84\uff0c\u4e5f\u4e3aPh+ ALL\u60a3\u8005\u6cbb\u7597\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u6ce8\u518cII\u671f\u7684\u6570\u636e\u66f4\u65b0\u4e3a\u4e0d\u540c\u4eba\u7fa4\u7684\u4e2a\u4f53\u5316\u7528\u836f\u63d0\u4f9b\u4e86\u91cd\u8981\u53c2\u8003\uff0c\u5728\u9ad3\u7cfb\u80bf\u7624\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u4f7f\u6211\u4eec\u5bf9\u5176\u5728\u8fd9\u7c7b\u60a3\u8005\u7684\u5e94\u7528\u5145\u6ee1\u4fe1\u5fc3\u3002\u7279\u522b\u662f\u4e24\u4e2a\u4ea7\u54c1\u7684\u8054\u7528\u6570\u636e\u5448\u73b0\u7684\u5f3a\u52b2\u6f5c\u529b\u8ba9\u6211\u4eec\u500d\u611f\u5174\u594b\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u52a0\u901f\u63a8\u8fdb\u4e24\u4e2a\u91cd\u78c5\u4ea7\u54c1\u7684\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u540c\u65f6\u79ef\u6781\u63a2\u7d22\u66f4\u591a\u521b\u65b0\u8054\u5408\u6cbb\u7597\u65b9\u6848\uff0c\u4e3a\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u53d8\u9769\u610f\u4e49\u7684\u6cbb\u7597\u9009\u62e9\u3002&#8221; \u5728\u6b64\u6b21EHA\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u7cbe\u9009\u58c1\u62a5\u6838\u5fc3\u8981\u70b9\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u79cd\u76f8\u5173\u7814\u7a76\u6570\u636e\u8bf7\u67e5\u8be2EHA\u5b98\u7f51\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u4e3a\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7ebf\u6cbb\u7597\u7684\u6700\u65b0\u7597\u6548\u4e0e\u5b89\u5168\u6027 \u6458\u8981\u7f16\u53f7\uff1aEHA-3388 (PS1733)\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7eac\u660e\u6559\u6388\uff0c\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u534f\u548c\u533b\u9662\u8840\u6db2\u79d1\u5173\u952e\u4fe1\u606f\uff1a\u8fd9\u662f\u4e00\u9879\u5355\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6807\u7b7e\u7684II\u671f\u7814\u7a76\uff0c\u8bc4\u4f30\u4e86\u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u65e0T315I\u7a81\u53d8\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08CCyR\uff09\u7387\u8fbe76.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\uff08MMR\uff09\u7387\u8fbe47.6%\uff0c\u4e14\u53cd\u5e94\u7387\u968f\u6cbb\u7597\u5468\u671f\u9012\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u65e0\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002\u8be5\u7814\u7a76\u8bc1\u660e\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u5728\u65e0T315I\u7a81\u53d8\u7684\u4e00\u7ebfTKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7597\u6548\u679c\uff0c\u4e3a\u8fd9\u7c7b\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7ebf\u6cbb\u7597\u9009\u62e9\u3002 EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u65e2\u5f80\u5bf9\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u836f\u4e14\u643a\u5e26ASXL1\u57fa\u56e0\u7a81\u53d8\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7597\u6548 [&hellip;]","og_url":"https:\/\/moneycompass.com.my\/cn\/\u3010eha2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\/","og_site_name":"Money Compass CN","article_published_time":"2026-06-15T01:25:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/","url":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/","name":"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b - Money Compass CN","isPartOf":{"@id":"https:\/\/moneycompass.com.my\/cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#primaryimage"},"image":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#primaryimage"},"thumbnailUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-wvESxR.jpeg","datePublished":"2026-06-15T01:25:00+00:00","dateModified":"2026-06-15T01:25:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#primaryimage","url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-wvESxR.jpeg","contentUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-wvESxR.jpeg","width":144,"height":54},{"@type":"BreadcrumbList","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90eha2026%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e4%b8%b4%e5%ba%8a%e6%95%b0%e6%8d%ae%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e6%98%be%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/moneycompass.com.my\/cn\/"},{"@type":"ListItem","position":2,"name":"\u3010EHA2026\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u4e34\u5e8a\u6570\u636e\u4eae\u76f8\uff0c\u5f70\u663e\u8840\u6db2\u80bf\u7624\u9886\u57df\u5168\u7403\u521b\u65b0\u5b9e\u529b"}]},{"@type":"WebSite","@id":"https:\/\/moneycompass.com.my\/cn\/#website","url":"https:\/\/moneycompass.com.my\/cn\/","name":"Money Compass CN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/25221"}],"collection":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/comments?post=25221"}],"version-history":[{"count":0,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/25221\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media\/25222"}],"wp:attachment":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media?parent=25221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/categories?post=25221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/tags?post=25221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}